COLORADO SPRINGS, Colo. – North Star announced today it has finished its very first inspection that is physical the U.S. Drug Enforcement Administration (DEA). North Star intends to be the leader in pharmaceutical grade cannabis production with facilities encompassing over 140 acres of outdoor cultivation and over 500,000 square feet of greenhouse and indoor cannabis cultivation.
John Kaweske, CEO of North celebrity states, “The Company thinks these applications will place North celebrity among the biggest businesses in terms of square footage and range licenses submitted by a operator that is single cannabis research in the United States. Our clients that are intended universities, pharmaceutical and biotechnology businesses. We plan to provide these scientists cannabis that are numerous varieties to choose from in order to conduct research. Cannabis research may unlock drug that is new for future FDA approved treatments.”
The University of Mississippi may be the only cannabis that are DEA-licensed for research purposes in the United States. North Star is hopeful that 2021 marks a era that is new of entities and federal agencies employed in cooperation to conduct cannabis research to greatly help produce brand new therapeutics.
About North Star
Since 2015, John Kaweske, CEO of North celebrity is forging a path into the cannabis that are regulated in multiple states by opening new markets, locations, and introducing brands focused on providing the best products for patients and consumers at affordable prices. North Star and its affiliates own and operate multiple medical and marijuana that is retail, thousands of square legs of cultivation facilities, removal laboratories, beneath the brands Tweedleaf, Xleaf and Leaf laboratories into the western usa. To learn more about North celebrity, contact Welby Evangelista at 801-946-2243 or via e-mail at [email protected]. Find out more about North Star Holdings at www.northstarholdings* that is.com(